Skip to content

Visio-conference for Pre-hospital Triage of Stroke Suspicions

Pre-hospital Optimization of Triage of Stroke Suspicions: Bringing an Embedded Visio Conference Device

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04042584
Acronym
OPTIC-AVC
Enrollment
215
Registered
2019-08-02
Start date
2019-11-20
Completion date
2021-12-09
Last updated
2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebrovascular Disorders, Stroke, Stroke, Acute, Stroke, Ischemic

Keywords

Stroke, Mechanical thrombectomy, Tele-evaluation, Emergency medical service, Pre hospital

Brief summary

Interventionnal Study to investigate the accuracy of our clinical based algorithm performed by using a visioconference device to assess the eligibility of acute recanalisation treatment (intraveinous thrombolysis (IVT) and/or mechanical thrombectomie (TM). Clinical identification of type of treatment is needed is pre-hospital triage of these patients.

Detailed description

The outcome of ischemic stroke (IS) with large artery occlusion (LVO) is related to the volume of infarcted brain witch is related to the delay of arterial recanalisation. IVT is available in multiple stroke units in France but, in case of LVO, the association with TM is needed. The availability of endovascular capable centers is limited to tertiary care hospitals. As a result, pre-hospital identification of these patients is a priority and the optimization of the triage can be done by a clinical algorithm carried out by a neurological tele-evaluation. OPTIC-AVC is a multi-phase study. This phase is about the evaluation of accuracy of our algorithm performed by a quick and standardized neurological tele-evaluation to predict the eligibility for recanalisation treatment (IVT and/or TM) of patients suspected of acute stroke in the emergency setting. The effective therapeutic decision for each patient, performed by another neurologist, will be blind to the theoretical therapeutic decision resulting from the algorithm. Theoretical and effective therapeutic decision will be compared a posteriori

Interventions

PROCEDUREVisio conference device evaluation (DVCM)

Standard neurological tele-evaluation (limited to 15minutes) remotely carried out by a first neurologist via a tablet (DVCM) and an operator. A second neurologist assist at the assessment without intervention next to the patient. Once the remote assessment is complet, the second neurologist ensure the continuation of standard patient care.

Sponsors

University Hospital, Bordeaux
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age over 18 * Suspicion of acute symptomatic stroke whose first symptoms are less than 24 hours old * Free Consent, informed writing signed by the participant or the person of confidence and the investigator (no later than the day of inclusion and before any examination required by research)

Exclusion criteria

* Stupor or coma requiring orotracheal intubation * Rankin pre stroke \> 4 * Severe cognitive impairement * Contraindication to the realiszation of angiographic imaging * Participation refusal * Patient under legal protection

Design outcomes

Primary

MeasureTime frameDescription
Final effective therapeutic decisionDay 0Thrombolysis and/or thrombectomy : yes/no

Secondary

MeasureTime frameDescription
Therapeutic convictionDay 0Theoretical conviction using Likert scales between the neurologist at the patient bedside and the neurologist using the device for tele-evaluation
Remote evaluation failureDay 0Remote evaluation failure rate
Theoretical therapeutic decisionDay 0Theoretical therapeutic decision of the algorithm : thrombolysis and/or thrombectomy \[yes/no\]

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026